EGFR and non-small cell lung carcinoma: Here, we utilized a large, nation-wide cohort of consecutive patients with advanced, metastatic EGFR-mutant NSCLC to report the therapeutic strategies and outcomes of patients treated in a real-world setting, with a focus on CNS metastases.